In recent years, targeting overexpressed receptors on tumor cells with radiolabeled peptides has become very important in anticancer therapy [48], so we decided to investigate two novel radioconjugates based on VEGF-A165/NRP-1 inhibitors: the A7R peptide and Lys(hArg)-Dab-Pro-Arg peptidomimetic. This evidence concerns the gene NRP1 and neoplasm.